| Literature DB >> 17969401 |
V F Semiglazov, V V Semiglazov, G A Dashian, E K Zhil'tsova, V G Ivanov, A A Bozhok, E E Tonuzov, R M Paltuev, O A Mel'nikova, A A Klettsel', P V Krivorot'ko, R V Donskikh, I A Kochetova, A O Damenia, K Iu Zernov, D A Voskresenskiĭ, L M Bershteĭn.
Abstract
Data are presented on a randomized study (stage II) which was undertaken to assess the efficacy of neoadjuvant chemotherapy (doxorubicin+paclitaxel) vis-a-vis endocrine therapy with aromatase inhibitors (anastrazole or exemestane) in postmenopausal women with ER-positive and/or PgR-positive tumors. Preoperative neoadjuvant chemotherapy was well tolerated and showed similar rates of overall response as compared with the latter regimen.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17969401
Source DB: PubMed Journal: Vopr Onkol ISSN： 0507-3758